Mahajan Anushi, Kedige Suresh
Department of Periodontology and Oral Implantology, Christian Dental College, Ludhiana, Punjab, India.
Department of Periodontology and Oral Implantology, M.M. College of Dental Sciences and Research, Mullana, Ambala, Haryana, India.
Dent Res J (Isfahan). 2015 Jan-Feb;12(1):25-30. doi: 10.4103/1735-3327.150307.
Bone loss is one of the hallmarks of periodontitis. Hence, a major focus of research into periodontal regeneration has concentrated on the initiation of Osteogenesis. Osteoinduction requires the differentiation of mesenchymal cells into osteoblasts with subsequent formation of new bone. The present study has been carried out to evaluate periodontal bone regeneration in intrabony defects using osteostimulative oleaginous calcium hydroxide suspension Osteora(®) (Metacura, Germany) in combination with osteoconductive bone graft Ossifi™ (Equinox Medical Technologies, Holland).
A total of 22 sites in patients within the age range of 25-50 years, with intrabony defects were selected and divided into two groups (Group A and Group B) by using the split-mouth design technique. All the selected sites were assessed with the clinical parameters such as - Plaque Index, Gingival Index, Sulcus Bleeding Index, Periodontal Probing Depth, Clinical Attachment Level, Gingival Recession and radiographic parameter to assess the amount of Defect Fill. Mann-Whitey U-test and Wilcoxon Signed Rank Test has been used to find the significance of study parameters on continuous scale for the comparison between the mesial and distal bone levels. P < 0.05 was considered to be statistically significant.
Osteora(®) in combination with osteoconductive Ossifi™ showed better regenerative potential and more significant amount of bone fill in periodontal intrabony defects than when Ossifi™ was used alone (P = 0.039).
Osteora(®) can be used as an adjunct to osteoconductive bone grafts, as an osteo-stimulating agent in the treatment of periodontal intrabony defects.
骨质流失是牙周炎的标志之一。因此,牙周再生研究的一个主要重点集中在成骨作用的启动上。骨诱导需要间充质细胞分化为成骨细胞并随后形成新骨。本研究旨在评估使用骨刺激油性氢氧化钙悬浮液Osteora®(德国Metacura公司)与骨传导性骨移植材料Ossifi™(荷兰Equinox Medical Technologies公司)联合治疗骨内缺损时的牙周骨再生情况。
选取年龄在25 - 50岁之间、患有骨内缺损的患者共22个部位,采用分口设计技术将其分为两组(A组和B组)。所有选定部位均通过菌斑指数、牙龈指数、龈沟出血指数、牙周探诊深度、临床附着水平、牙龈退缩等临床参数以及用于评估缺损填充量的影像学参数进行评估。采用曼 - 惠特尼U检验和威尔科克森符号秩检验来确定研究参数在连续尺度上对于近中骨水平和远中骨水平比较的显著性。P < 0.05被认为具有统计学意义。
与单独使用Ossifi™相比,Osteora®与骨传导性Ossifi™联合使用在牙周骨内缺损中显示出更好的再生潜力和更显著的骨填充量(P = 0.039)。
Osteora®可作为骨传导性骨移植材料的辅助剂,作为治疗牙周骨内缺损的骨刺激剂。